Current Neuro-Oncology

Volume 27 Number 14
20 May 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 14, 20 May

*Fanizzi C, Bintintan-Socaciu P, Pirola E, Fiore G, Carnicelli I, Tariciotti L, Parlangeli A, Scagliotti E, Tabano SM, Lopez G, Ferrero S, Navone S, Guarnaccia L, Marfia G, Caroli M, Locatelli M.
Optimal MGMT promoter methylation cut-off to predict better survival in glioblastoma patients undergoing gross-total resection.
J Neurosurg Sci. 2025 May 12. doi: 10.23736/S0390-5616.25.06421-5. PMID: 40351039. Observational study˰ ˍ

Jiang Z, Cai C, Shaikh N, Hyman W.
Glioblastoma with metastasis to the bone marrow.
BMJ Case Rep. 2025 May 12;18(5):e260883. doi: 10.1136/bcr-2024-260883. PMID: 40355275. Case report˰ ˍ

Sincari A, Yousif S, Robertson T, Huang YT, Alexander H.
Adult H3 K27-altered, H3.3 K27-mutant diffuse midline glioma affecting the conus medullaris: illustrative case.
J Neurosurg Case Lessons. 2025 May 12;9(19):CASE24879. doi: 10.3171/CASE24879. PMID: 40354758. Case report. ˍ

*Semiz V, Cetinayak HO, Aydin B, Umay C, Can F.
Surgery to chemoradiotherapy time may not impact outcomes in glioblastoma patients treated with modern techniques: a single-institution study.
Radiol Oncol. 2025 May 14. doi: 10.2478/raon-2025-0031. PMID: 40366817. Observational study. ˍ

Lazarev S, Sindhu KK.
The INDIGO Illusion: The Evidence Still Supports Chemoradiation Therapy in Patients with Low-Grade Glioma.
Int J Radiat Oncol Biol Phys. 2025 May 15;122(2):222. doi: 10.1016/j.ijrobp.2024.12.048. PMID: 40382161. Point of view. ˍ

Singh R, Palmer JD.
INDI-NO-GO: A Recommendation for Caution with Use of Isocitrate Dehydrogenase Inhibitors for High-Risk, Low-Grade Gliomas.
Int J Radiat Oncol Biol Phys. 2025 May 15;122(2):223. doi: 10.1016/j.ijrobp.2025.01.019. PMID: 40382163. Point of view. ˍ

Eid M, Alset D, Timoshkina N, Gvaldin D, Rostorguev E, Kavitskiy S, Novikova I.
IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study.
J Egypt Natl Canc Inst. 2025 May 16;37(1):36. doi: 10.1186/s43046-025-00296-w. PMID: 40377745. Observational study. ˍ

Muragaki Y, Ishikawa E, Tamura M, Kawamata T, Gosho M, Hashimoto K, Komori T, Yokoo H, Matsutani M, Maebayashi K, Tanaka T, Yamaguchi S, Kanamori M, Yamamoto T, Hanihara M, Arakawa Y, Sasayama T, Abe T, Nakamura H, Mukasa A, Uzuka T, Nakajo K, Ohno T.
A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol.
Jpn J Clin Oncol. 2025 May 16:hyaf078. doi: 10.1093/jjco/hyaf078. PMID: 40377260. Interventional study protocol˰ ˍ

Gao C, Su B, Luan G, Lei D, Lu Y, Zhang H, Wang G, Jing L.
Clinical Prognostic Factors and Molecular Characteristics of Spinal Cord Diffuse Midline Gliomas.
Neurosurgery. 2025 May 19. doi: 10.1227/neu.0000000000003527. PMID: 40387326. Observational study. ˍ

Zhang R, Jiang G, Ren Y, Zhang Y, Niu X.
Clinical Nomogram Model for Predicting the Prognosis of Patients with Brainstem Glioma : A Population-based Study.
J Korean Neurosurg Soc. 2025 May 20. doi: 10.3340/jkns.2025.0037. PMID: 40390531. Observational study. ˍ